Delivery Order SPE2DB22D3011-SPE2DB25FQ2GG
- Not listed
- The Defense Logistics Agency awarded a $7,046.76 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a $8,222.46 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 15, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $38,034.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract, which is not set-aside and was competitively awarded, requires completion by June 18, 2025, with performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,346.36 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes. The contract, executed on August 6, 2025, with an ultimate completion date of August 7, 2025, operates under firm fixed-price terms with no set-aside designation. Performance will take place at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.73 to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 MG/4 ML syringes (4 ML quantity) on August 12, 2025, with a completion date of August 13, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate...
- The Defense Logistics Agency's Medical Supply Chain awarded a $14,790.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 22, 2025, with completion targeted for August 25, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the company's primary mechanism for...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.92 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 27, 2025, with completion scheduled for August 28, 2025. This non-competitive, firm fixed-price delivery order represents a single procurement under AmerisourceBergen's larger contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, which serves as...
- The Defense Logistics Agency awarded a $3,614.94 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion by June 2, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,019.91 to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award to a qualified vendor. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $6,708.32 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on July 24, 2025, with completion expected by July 25, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2GGDelivery Order
The Defense Logistics Agency awarded a $2,194.02 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical supply vendor that serves military and veteran healthcare systems through the Defense Logistics Agency. The company's comprehensive federal contract portfolio includes pharmaceutical products, medical devices, vaccines, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for Monovisc—a hyaluronic acid viscosupplement used primarily for knee osteoarthritis treatment—reflects the vendor's ongoing role in supporting Department of Defense medical supply chains and demonstrates the versatility of the prime vendor global contract structure in fulfilling specialized medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/15/25 |